NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma

Vilde Drageset Haakensen, Anna K. Nowak, Espen Basmo Ellingsen, Saima Jamil Farooqi, Maria Moksnes Bjaanæs, Henrik Horndalsveen, Tine Mcculloch, Oscar Grundberg, Susana M. Cedres, Åslaug Helland

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds